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Running title: Undifferentiated pancreatic carcinoma with osteoclastic giant cells  
 
 
Summary Statement: Undifferentiated pancreatic carcinoma with osteoclastic giant cells is a 
rare malignant tumor that is typically large, frequently has a ductal component and shows three 
classical cell types including benign osteoclastic giant cells, and malignant pleomorphic giant 
cells and spindled/histiocytoid tumor cells, making cytologic diagnosis possible in most cases.  
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Abstract 
Background: The cytologic features of undifferentiated pancreatic carcinoma with osteoclastic 
giant cells (UOC) are rarely described. 
Methods: Cytologic and clinicopathologic characteristics in 15 UOC FNAs were analyzed. 
Results: 6 males, 8 females, mean age 65, had UOCs [head (7), body (3) and tail (4)] of mean 
radiologic size 7.3 cm with cystic component (9). Three cell types [osteoclastic giant cells (OGC), 
pleomorphic giant cells (TGC) and spindled/histiocytoid cells (SHC)] were seen in 12/15 (80%).  
Pancreatic ductal adenocarcinoma (PDAC) was present in 11. FNA diagnoses were: UOC (6), 
PDAC (5), poorly-differentiated carcinoma (2), “suspicious for neoplasm” (1) and “negative” (1). 
OGCs were CD68+ in 5/5. Pancytokeratin (6/7), CAM5.2 (2/3), and EMA (2/2) highlighted TGCs 
and SHCs. INI-1 was retained in 3/3 cases. Ki-67 index was performed in 3 cases and was 12, 18, 
and 40%; 4/12 resected UOCs were pure and 8 were mixed with PDAC; 1 resection had 
intraductal papillary mucinous neoplasm and 2 had mucinous cystic neoplasms. Median overall 
survival (OS) of FNA’ed UOCs was 8 mths [6 died (OS 8 mths; 2 -22) and 8 were alive (OS 3 mths; 
1 – 27)], which was similar to 74 FNA’ed PDACs (OS 15 mths; p=0.279) but worse than 27non-
FNA’ed UOCs (OS 92 mths; p=0.0135).  
Conclusion: The 3 classical UOC cell types are identifiable on FNA, making cytologic diagnosis 
possible if considered in the differential. A PDAC component is also often seen. The survival 
advantage of UOC over pure PDACs appears to be negated by FNA and requires further 
investigation.  
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Introduction 
The vast majority of pancreatic masses represent ductal adenocarcinoma (PDAC), which has a 
dismal 5-year survival of less than 8%, and is currently the third leading cause of cancer-related 
deaths in the United States.
1
 Undifferentiated pancreatic carcinoma with osteoclastic giant cells 
(UOC) is an extremely rare pancreatic cancer that has a preponderance of osteoclastic giant 
cells showing all the characteristics of osteoclasts of bone. It was first described by Sommers et 
al in 1954 as “unusual carcinoma of pancreas”.
2
 In 1968 Rosai named these tumors “carcinomas 
of pancreas simulating giant cell tumor of bone”.
3
 Its’ true incidence remains unknown because 
of the plethora of names by which it has been described including “pleomorphic carcinoma of 
pancreas”, “giant cell carcinoma”, “osteoclastic giant-cell tumor or carcinoma”, “sarcomatoid 
carcinoma” and “carcinosarcoma” to name a few. In the 2010-World Health Organization book 
these tumors were classified as “variants” of pancreatic ductal adenocarcinoma under the 
heading “undifferentiated carcinoma with osteoclastic giant cells”, 
4
 and are  fundamentally 
epithelial derived tumors with mesenchymal differentiation.
3, 5
   
 
The average patient age is 62 years but age varies widely from 32 – 93 years.
4, 6-8
 Tumors are 
typically large and circumscribed, and are defined by non-neoplastic, phagocytic, osteoclastic 
giant cells containing over 20 bland nuclei, in a background of “sarcomatoid” carcinoma, which 
may produce osteoid.
6, 8-10
 Some tumors show polypoid intraductal or intra-ampullary growth 
or cystic degeneration, 
8, 11, 12
 while others arise in neoplastic mucinous cysts (mucinous cystic 
neoplasm (MCN) or intraductal papillary mucinous neoplasm (IPMN)).
8, 13-15
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Other than the macrophage-like osteoclastic giant cells that are typical of this tumor,
9
 two 
other distinct tumor cell types, including large, highly pleomorphic mononuclear tumor giant 
cells as well as small spindled or histiocytoid tumor cells sometimes resembling stromal cells 
may be seen. Osteoclastic giant cells have been shown by morphologic, immunohistochemical, 
molecular and ultrastructural studies to represent benign histiocytic cells likely recruited by the 
tumor’s sarcomatoid component.
9, 16
 Elevated chemoattractants noted in oral squamous and 
inflammatory breast cancers have been postulated to play a similar chemotactic role in some 
pancreatic and ampullary cancers, including UOC.
8, 17, 18
  
 
Osteoclastic giant cells express CD68, vimentin, leukocyte common antigen, and are negative 
for keratin and p53; however, the truly malignant cells in this tumor, i.e. the pleomorphic tumor 
giant cells and spindled or histiocytoid cells (that are often overlooked in the background), 
strongly express vimentin, and variably, but typically, express keratin, show mutant p53 staining 
pattern (with diffuse positivity) and elevated Ki-67 proliferation index.
4, 8-10, 19, 20
 UOCs 
frequently show an associated component of conventional PDAC.
4, 8
 While some studies 
suggest an overall poor prognosis for UOC, with mean survival of 12 months,
4, 7
 more 
recent studies have shown these tumors to have a more protracted clinical course relative to 
conventional PDAC.
8, 21-23
 
 
While the histologic features of UOC (a.k.a. “osteoclastic giant cell carcinoma”) are well known 
its cytologic features are only rarely described and mostly as isolated reports or small series.
12, 
24-38
 We herein present the cytologic findings in 15 fine needle aspirations (FNAs) defined by the 
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presence of osteoclastic giant cells, and highlight useful diagnostic cytologic characteristics as 
well as pertinent clinicopathologic features and associations. To date, this is the largest 
cytologic series in the English literature. 
 
Materials and Methods 
A multi-institutional pathology database search yielded 15 FNAs from 14 patients, including 6 
from Emory University’s archives and consultation files, 2 each from Thomas Jefferson 
University, Philadelphia, PA, University of Michigan, Ann Arbor, MI and University of British 
Columbia, Vancouver, BC and 1 each from Northside Hospital, Atlanta, GA, Mayo Clinic, 
Rochester, MN, and Cleveland Clinic, Cleveland, OH. Resected pure undifferentiated carcinoma 
lacking osteoclastic giant cells were excluded from analysis. 
 
All patients had image-guided (endoscopic ultrasound (n=11) or computerized tomography 
(n=3)) FNAs, with or without on-site evaluation, with 1 – 7 passes per patient (mean 3.9).  Cyst 
fluid analysis and molecular studies were not performed on the specimens. Cytologic material 
including smears, ThinPrep®, cellblocks and immunocytochemical stains (when available) were 
reviewed. On average, 7 slides were available per case (range 2 – 19), including both 
Papanicolaou and Diff Quik. Core biopsies were also available for review in 1 patient (# 14).  
 
Twelve of 14 patients (86%) had follow-up resections and the tumors’ clinicopathologic 
characteristics were documented. Additionally, cytologic samples were analyzed for the 
presence and frequency (focal (1), moderate (2) or extensive (3)) of four cell types: (1) 
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osteoclastic giant cells (OGCs), (2) spindled or histiocytoid tumor cells (SHCs), (3) mononuclear 
pleomorphic tumor giant cells (TGCs), (4) PDAC component. Necrosis and acute inflammation 
was also documented. 
 
Comparison of Survival Differences between Aspirated UOCs, UOCs with No Prior FNA and 
Conventional PDAC with Prior FNA 
The survival of the FNA’ed UOC patients (n=14) was contrasted with a cohort of unaspirated, 
resected UOCs in the authors’ database (n=27), the detailed analysis of which was already 
published,
8
  as well as a cohort of conventional PDACs that had been subjected to FNA (n=74). 
 
Results 
Clinical Characteristics 
The 15 specimens were from 14 patients including 6 males and 8 females, ranging in age from 
35-77 years (mean, 65.3 years). Seven were in the pancreatic head, 3 the body and 4 in the tail.  
Clinicopathologic findings are summarized in Table 1. 
 
Radiologic Findings 
On imaging tumors ranged in size from 2.0 – 15 cm (mean, 7.3 cm) and were either purely cystic 
(n=2, one was suspicious for a pseudocyst), purely solid (n=3, with radiologic diagnoses of PDAC 
in 2 and sarcoma in 1), or mixed cystic and solid masses (n=9). Other radiologic diagnoses 
included IPMN and cystic pancreatic neuroendocrine tumor (PanNET), among others (Table 1). 
Interestingly, only one tumor, a 9.0 cm solid pancreatic mass, was called sarcoma on imaging.  
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Cytologic Findings 
Diff Quik, Papanicolaou smears and ThinPrep® slides ranged from moderately cellular (14/15 
cases, 93%) to hypocellular (1/15; 7%). There were three distinct types of tumor cells: (1) 
multinucleated osteoclastic giant cells, (2) large pleomorphic tumor giant cells and (3) smaller 
spindled or histiocytoid cells (Figure 1 -5). Malignant pleomorphic giant and 
spindled/histiocytoid cells were in clusters, syncytial groups and singly dispersed, with high 
nuclear to cytoplasmic ratio and nuclear irregularity (both present in 12/15, 80%) (Figure 1-5). 
Additionally, variable numbers of multinucleated osteoclast-like giant cells, ranging in size from 
50 – 500 microns, were seen in 12/15 (80%) FNAs (Figure 1 - 2). Of the 3 FNAs that lacked all 
three cell types one represented a 25cm MCN with a 2.0 cm UOC focus that was likely not 
sampled by FNA, another (case # 15) was almost exclusively PDAC with only scattered small 
patches of UOC component (of overall estimated size < 0.5 cm) identified only on the resection 
specimen, and the third case (case # 6) had acellular smears, with rare atypical glandular cells 
on cellblock but was called “negative” on initial cytologic diagnosis. Mitotic figures were 
identified in rare tumor nuclei (Figure 3). Background necrotic debris (12/15, 80%) and a 
neutrophilic inflammatory infiltrate (6/15, 40%) were seen in several (Figure 2).  
 
On Papanicolaou-stained slides (smears and ThinPrep® slides), cellblocks and cores the 
osteoclastic giant cells were easily identifiable, with multiple (10 or more) centrally clustered 
oval or raisinoid nuclei, indistinct nucleoli and abundant pale blue- grey or eosinophilic 
cytoplasm (Figure 1 and 2). The spindled/histiocytoid cells ranged from long, slender and 
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atypical to round and bland (Figure 1).  Pleomorphic tumor cells had large bizarre hyper- to 
hypochromatic nuclei, and were single-lobed or polylobated, some with mummified features, 
and macronucleoli (Figure 1 and 3). In all cases, tumor giant cells were the most frequent, 
followed by spindled or histiocytoid cells then osteoclastic giant cells.  
 
An adenocarcinoma component was notable on smears in 11/15 (73%) cases. These were 
represented by sheets, clusters or singly dispersed malignant epithelial cells, with or without 
cytoplasmic mucin vacuoles or overt gland formation (Figure 4). The corresponding resections 
in these 11 cases also showed a PDAC component.  
 
Cell blocks were available for review in 13/15 (87%) specimens and were very helpful in 
supporting the diagnosis as they often showed the osteoclastic giant cells (Figure 1 and 2). 
Single cell necrosis and confluent necrosis were present in 12/15 (80%) cases. A core biopsy had 
also been performed in case #14 and showed the 3 classical cell types of UOC (Figure 5). 
Cytologic findings are summarized in Table 2. 
 
The final diagnoses in associated cytopathology reports were UOC (6/15; 40%), poorly 
differentiated carcinoma (2/15; 13%), “suspicious for neoplasm” (1/15; 7%), “negative for 
malignant cells”(1/15; 7%) and PDAC (5/15; 33%), one (case #7) arising in a neoplastic mucinous 
cyst which on FNA showed mucinous epithelium with high-grade atypia and necrosis. 
Interestingly, on re-review the “negative” case (case # 6) in hindsight would best have been 
interpreted as “atypical cells present or suspicious for adenocarcinoma” since the cell block 
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showed a single highly atypical gland, while the smears were mostly acellular.   
 
Immunocytochemical Findings 
Immunocytochemical stains were performed in several cases and showed the following 
pertinent results: CD68 (a histiocytic marker) was diffusely and strongly positive in osteoclastic 
giant cells (5/5 cases) and focally positive in rare isolated histiocytoid cells. Epithelial markers 
were frequently positive, albeit focally, in tumor giant cells and spindled or histiocytoid tumor 
cells; pancytokeratin was positive in 6/7 cases tested and was stronger in tumor giant cells; 
CAM 5.2 and epithelial membrane antigen (EMA) were focally positive in tumor giant cells and 
spindled or histiocytoid tumor cells in 2/3 and 2/2 cases respectively; 1 showed a mutant p53 
pattern (diffuse, strong positivity) while p53 was negative in 2 cases (Figure 5). INI-1 which has 
recently been shown to be a marker of a specific subset of undifferentiated carcinoma of 
pancreas (typically without OGCs),
39
 was retained in all 3 tested tumors. Additional pertinent 
negative stains include S100 in 3/3 cases. Interestingly Ki-67 immunostain was performed in 3 
tumors and the proliferation index was 12, 18, and 40% respectively.  
 
Histologic Findings in the 12 Resected Cases 
Tumors were located in the pancreatic head (n=6), body (n=2) and tail (n=4) and resections 
included 6 pancreatoduodenectomies and 6 distal pancreatectomies. Two tumors were not 
resected. Tumors ranged in size from 0.6 – 13.0 cm (mean, 6.9 cm) and were mostly 
demarcated and solid, with a cystic component in 11 cases; 3/11 cystic tumors had associated 
neoplastic mucinous cysts (IPMN with high-grade dysplasia (n=1) and MCN with high grade 
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dysplasia (n=2)). Of the 12 resections, 4 (33%) were pure UOC and 8 (67%) had admixed PDAC, 
ranging from focal (10% in 5) to extensive (30-90% in 3) (Figure 1). One unresected tumor was a 
pure UOC on FNA and core biopsy, while the other was “mixed”. The 12 resections had lymph 
node sampling (15 – 33 lymph nodes) and four patients had lymph node metastasis. One 
patient (case # 8) had liver metastasis at the time of pancreatectomy. Lymph-vascular and 
perineural invasion were seen in 5 (42%) and 6 (50%) cases respectively and tumor margins 
were positive in 1/12 (8%). Regarding pathologic(p) TNM stage (per American Joint Committee 
on Cancer; Cancer Staging Manual 7
th
 edition),
40
 one (8%) was pT1N0MX, four (33%) were 
pT2N0MX, five (42%) were pT3N0MX, one (8%) was pT3N1MX and one (8%) was pT3N1M1. 
One unresected tumor was staged as T3N1M1 (case #14) based on markedly enlarged 
peripancreatic lymph nodes and a large liver mass on imaging.  
 
Follow-up Information 
At an overall median follow-up period of 5 months (range 1-27), one patient died of peri-
operative complications, 8 were alive (6 with no evidence of disease, and 2 with liver 
metastasis; median survival, 3 months (range 1-27)), 6 were dead of disease (1 – 21 months), 
and one was lost to follow up at 3 months (Table 3). Chemotherapy was given to 5 patients 
(survival 1 – 27 months), 3 of whom were alive at last follow-up, one was dead (survival 10 
months) and the fifth was lost to follow-up after chemotherapy. See Table 1 for detailed length 
of survival of each patient. 
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Comparison of Survival between Aspirated UOCs, UOCs without Prior FNA and Conventional 
PDACs with Prior FNA 
When the FNA’ed UOC cohort (n=14) was compared to a cohort of UOCs that had not been 
previously aspirated but was not stage-matched (n=27), there was a statistically significant 
difference in survival between the two, with the FNA’ed UOCs showing significantly shorter 
median overall survival (8 months versus 92.4 months, p = 0.0135) than the UOCs that had not 
been aspirated before resection (Table 3, Figure 6). When the same FNA’ed UOCs (n = 14) were 
compared to an FNA’ed conventional PDAC cohort (also not stage-matched) (n=74), FNA’ed 
UOCs continued to trend toward shorter overall survival than the PDAC group (median survival 
8 versus 15 months), but this failed to reach statistical significance (p = 0.279). Meanwhile, 
there was a more striking survival advantage of the non-FNA’ed UOCs (n=27) compared to the 
74 FNA’ed PDACs, but this fell short of statistical significance (p=0.058). 
 
Discussion 
Unique cytologic features of UOCs include a mixture of large, bland, multinucleated, 
osteoclastic giant cells as well as highly pleomorphic malignant tumor giant cells and small 
spindled or histiocytoid tumor cells. These are often present in a background of necrosis and 
variable neutrophilia, and may be associated with a conventional PDAC component, a frequent 
finding on FNA of UOCs.
34
   
 
The three classical cell types of UOC are identifiable on FNA in the majority of cases, making 
cytologic distinction possible if this entity is considered in the differential. This was not just 
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evident in our cohort but others’.
31, 34, 37, 38
 UOC is not only recognizable on FNA but also on 
brushings of its intraductal counterpart.
12
 The osteoclastic giant cells are perhaps easiest to 
recognize, and once identified, should prompt a search for the other two cell types. 
Interestingly, although only 40% of cases were correctly called UOC on cytology, review of the 
original cytology material of the remainder revealed that 60% of cases initially called PDAC, 
both “poorly differentiated carcinomas” and the “suspicious for neoplasm” case all had the 
three distinct tumor cell types typical of UOC, particularly osteoclastic giant cells. Thus, 80% of 
specimens could have been accurately identified as having a UOC component on FNA. Only 
three cases lacked all three cell types on FNA. One case showed features of a neoplastic 
mucinous cyst with high-grade atypia and was diagnosed on cytology as “(at least) 
adenocarcinoma in situ arising in a neoplastic mucinous cyst with high-grade atypia; suspicious 
for invasion”. On resection, this case turned out to be a 25.0 cm MCN with extensive high-grade 
dysplasia and a 2.0 cm focus of mixed UOC and PDAC, which was unlikely to have been sampled 
during FNA. Despite generous sampling in one case, only PDAC was identified on FNA, while the 
corresponding resection showed 90% PDAC and a very limited UOC component. 
 
In mixed cases the UOC component may be focal, emphasizing the importance of careful 
cytologic examination and histologic sampling. Additionally, for those with an extensive cystic 
component (whether due to degeneration or concomitant neoplastic mucinous cyst), the UOC 
component may be overlooked.  Tumors may also exhibit extensive fibrosis, hemorrhage and 
even osteoid formation, which can lead to non-diagnostic samples.  
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Tumors are known by names such as “osteoclastic giant-cell tumor of pancreas” and 
“pleomorphic (giant cell) carcinomas of pancreas”. 
36,34
  Some have suggested differences in 
behavior based on the amount of osteoclastic giant cells, with less aggressive behavior in 
tumors more rich in osteoclastic giant cells. It is important to note that all UOCs have similar 
behavior, despite the quantity of the three distinct cell types, including osteoclastic giant cells. 
 
The significance of a UOC component cannot be overstated as we showed in a recent histologic 
study of 38 UOCs that (whether pure or combined with PDAC), tumors with a UOC component 
have a more protracted clinical course with significantly longer 5-year survival than 
conventional PDAC (59.1 versus 15.7% in poorly differentiated PDACs).
8
 This suggests that UOCs 
should be resected once identified, if patients are good surgical candidates. However, an 
interesting observation in our limited FNA cohort was the shorter survival of FNA’ed UOCs 
which was very similar to, if not worse than that of PDACs, while UOCs without an FNA prior to 
resection had a much better prognosis than both groups. This may be attributable to selection 
bias where patients with more aggressive UOCs were more likely to have diagnostic procedures 
perhaps because of symptoms. Additionally, the PDACs and non-FNA’ed UOCs were not stage-
matched with our cohort, which may also account for survival differences. Nevertheless, the 
shorter survival of FNA’ed UOCs relative to our previously studied UOC group raises concern for 
“whether FNA negatively impacts these tumors’ prognosis”. The FNA procedure is safe for the 
majority of tumors, including pancreatic ones. In fact, we recently analyzed our PDAC database 
comparing FNA’ed tail PDACs with those that had not been FNA’ed before resection and found 
survival to be identical in both groups (unpublished data). But it is possible that some tumors 
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(pancreatic colloid carcinoma and mixed salivary gland tumors) may spread after manipulation, 
and may require removal of the needle tract, similar to mixed salivary glands tumors.
41,42
  If this 
observation is ultimately confirmed by other studies, then UOC may prove to be one of those 
rare tumors with unique biological properties that create vulnerability to iatrogenic spread.  
 
The clinicopathologic characteristics in our cohort are similar to previous reports, in that our 
patients were predominantly female, of mean age 65 years, 
4, 6, 7, 10
 with large tumors (mean 6.9 
cm), many with a PDAC component and tumoral intraepithelial neoplasms (MCN and IPMN) in 
20%.
8, 13
 The coexistence of UOC with MCN and IPMN is well documented.
8, 13-15
 A cystic 
component (mostly cystic degeneration) was seen in most UOCs in our cohort. This can cause 
radiologic misdiagnosis as neoplastic mucinous cyst or pseudocyst, or limit sampling of the 
tumor’s solid component. Knowledge of the association between UOC and neoplastic mucinous 
cysts is critical in ensuring that resected mucinous cysts are extensively sampled, so as not to 
miss a UOC component. UOCs may also protrude as polyps into the pancreatic or bile duct, 
duodenum or ampulla, leading to radiologic misdiagnosis as IPMN, intra-ampullary tubulo-
papillary neoplasm or intraductal papillary neoplasm of bile duct.
8, 11, 12
  
 
Immunohistochemistry can be especially helpful in the cyto-histologic diagnosis of UOC as 
osteoclastic giant cells consistently express the histiocytic marker CD68 and are typically 
negative for epithelial markers and Ki-67.
8, 9
 Additionally, malignant pleomorphic tumor cells 
and spindled/histiocytoid tumor cells variably express pancytokeratin, CAM5.2 and EMA, which 
are typically negative in osteoclastic giant cells. Ki67 proliferation index is also high in these 
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cells. p53 may be expressed by malignant tumor giant cells and spindled or histiocytoid tumor 
cells but is negative in osteoclastic giant cells.
4, 8
 Only one of four UOCs in our cohort showed a 
mutant p53 staining pattern. 
 
The significance of the presence and amount of PDAC in these tumors has been previously 
studied, including by our group.
8
 In our prior study we found a PDAC component in 75% of 
cases however it had no effect on overall survival, when PDAC percentages were examined. 
 
Differential Diagnosis 
Multinucleated (reactive or neoplastic) giant cells can be seen in benign and malignant 
processes in the pancreas including chronic pancreatitis, PanNET and solid-pseudopapillary 
neoplasm (SPN).
35, 43, 44
 The highly atypical, hyperchromatic multinucleated giant cells in 
PanNETs represent neuroendocrine “atypia” of a symplastic nature, a well-known degenerative 
phenomenon with no clinical significance.
44
  Degenerating “cercariform” giant cells have also 
been described in SPN.
43
 In both PanNETs and SPN background tumor cells show the other 
cytologic characteristics that typify these neoplasms (such as plasmacytoid cells with salt and 
pepper chromatin in PanNETs and open chromatin and longitudinal nuclear grooves in SPN), 
facilitating distinction.   
 
A major differential of UOC is undifferentiated PDAC, NOS type. On cytology these tumors are 
highly pleomorphic with clustered or singly dispersed highly malignant cells with or without 
cytoplasmic mucin vacuoles but with high nuclear to cytoplasmic ratio, necrosis and brisk 
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mitotic activity. These tumors however lack osteoclastic giant cells which distinguishes them 
from UOC. Additionally tumor cells in undifferentiated PDAC are keratin positive and do not 
express histiocytic markers. Their prognosis however is typically much worse than UOC. 
 
Another “undifferentiated” pancreatic primary, undifferentiated rhabdoid carcinoma with KRAS 
alterations and SMARCB1 (INI-1) loss which was recently described by Agaimy et al, is an 
important differential.
39
 This tumor typically shows eosinophilic rhabdoid cells with 
pleomorphic nuclei and prominent nucleoli that may mimic the pleomorphic tumor giant cells 
of UOC. However, they either exhibit loss of INI-1 or show KRAS mutations, unlike UOC which to 
date has not been shown to have INI-1 loss. Undifferentiated rhabdoid pancreatic carcinomas 
do not contain osteoclastic giant cells.
39
 We performed INI-1 testing in three UOCs and it was 
retained in all three. 
 
Malignant melanoma frequently metastasizes to the pancreas and be confused with UOC.
45, 46
 
Melanoma tumor cells may be spindled or epithelioid and single, with prominent nucleoli that 
mimic UOC. Additionally, multinucleated tumor giant cells may be confused with the 
osteoclastic giant cells of UOC. However, melanoma is negative for histiocytic and epithelial 
markers and positive for melanoma markers S100, melan-A and HMB-45, which would be 
negative in UOC.  
 
While primary pancreatic sarcoma is uncommon, sarcoma metastasizing to pancreas (including 
leiomyosarcoma and rhabdomyosarcoma) is a known phenomenon.
45-47
 Such tumors are 
Page 19 of 41 Cancer Cytopathology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
20 
 
unlikely to show the bland osteoclastic giant cells of UOC, are typically more cellular and 
mitotically active than UOC, and are negative or only focally positive for epithelial markers. 
 
Another key differential is chronic pancreatitis with exuberant granulation tissue formation. 
When one of our cases (case # 3, a consult from an outside institution) was initially reviewed by 
five experienced pathologists at our intradepartmental conference, it was interpreted as 
chronic pancreatitis with exuberant granulation tissue formation, because it contained 
numerous foamy looking histiocytoid cells, giant cells and capillaries. Immunohistochemical 
stains had been performed by the submitting institution including pancytokeratin, CAM5.2, 
vascular markers (ERG and CD31), S100, CD45, ALK and CD35 (all of them negative). Despite 
strong CD68 and CD163 positivity in the osteoclastic giant cells a definitive diagnosis was not 
reached at the outside institution. EMA was performed at our institution and its positivity in the 
spindled and histiocytoid cells was helpful in leading to an accurate cytologic diagnosis of UOC.  
Additionally, ki-67 index was high in malignant cells. 
Conclusion 
In conclusion, undifferentiated pancreatic carcinoma with osteoclastic giant cells is a rare 
distinctive malignant pancreatic tumor that is typically large, frequently has a PDAC component 
and shows three classical cell types (osteoclastic giant cells, pleomorphic tumor giant cells and 
spindled or histiocytoid tumor cells), which make cytologic diagnosis possible in the majority of 
cases. Tumors show a strong association with mucinous tumoral intraepithelial neoplasms and 
have a propensity for cystic degeneration. While UOCs have been recently shown to have a 
better prognosis than that historically thought, the prognosis in our small cohort was poor, 
Page 20 of 41Cancer Cytopathology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
21 
 
raising the possibility of selection bias in subjecting more aggressive UOCs to FNA, versus a 
negative link between FNA and survival. Larger studies are needed to explore this association. 
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Table 1. Clinicopathologic Characteristics of Undifferentiated Pancreatic Carcinoma with Osteoclastic giant Cells (n=15) 
FNA
# 
Age Sex Location 
Imaging 
Modality 
Size on 
Imaging 
(cm) 
Additional 
Radiologic 
Findings 
Radiologic 
Diagnosis 
Cytologic 
Diagnosis 
Histologic 
Diagnosis 
Size of 
Invasion 
(cm) 
Follow-up 
(mths) 
1 
71 F Head MRI 7.2 
Clustered 
cysts w/  
septal 
enhancement
;  
No large solid 
component 
IPMN 
Poorly 
differentiated 
carcinoma 
Mixed  
UOC  
and  
PDAC 
3.0 
10 mths, 
LTF/U after 
chemo 
2 
Poorly 
differentiated 
carcinoma 
3 54 F Body N/A N/A N/A N/A UOC UOC 2.1 
2.2 mths, 
ALIVE, NED 
4 66 F Tail MRI 6.8 
Solid and 
cystic mass 
PDAC UOC 
Mixed  
UOC and  
PDAC 
7.1 
10.2 mths, 
DEAD w/ 
liver mets 
(PDAC 
component
) 
5 51 F Head CT 3.4 
Cystic mass 
w/ 
peripheral 
nodular 
components  
Cystic  
NET 
Suspicious for 
neoplasm 
Mixed  
UOC and 
PDAC  
5.4 
4.1 mths, 
Alive, NED, 
Received 
radiation 
6 75 F Head MRI N/A 
Pancreatic 
neck 
stricture, 
severe 
pancreatic 
duct 
dilatation;  
no 
measurable 
mass 
Chronic 
pancreatitis  
vs Tumor  
Negative for 
malignant 
cells 
Mixed  
UOC and 
PDAC 
0.6 
12.9 mths, 
DEAD 
7 35 F Tail MRI 25.0 
Complex 
solid and 
cystic mass  
PDAC 
PDAC  
possibly 
arising in  
NMC 
Mixed  
UOC and 
PDAC, 
MCN w/  
HGD 
2.5 
27 mths, 
ALIVE, NED 
8 49 F Tail MRI 5.6 
Cystic and 
solid mass 
Possible 
cystic NET 
PDAC 
UOC, 
PDAC and 
MCN 
1.0 
1.2 mths, 
ALIVE w/ 
UOC liver 
mets 
9 43 M Head CT 6.0 Cystic lesion Pseudocyst UOC UOC 6.5 
21.18 mths, 
DEAD 
10 77 F Head CT 9.0 Solid mass Sarcoma UOC N/A N/A 
1.7 mths, 
DEAD 
11 65 M Head EUS 2.0 Solid mass 
PDAC vs 
lymphoma 
PDAC 
UOC and 
PDAC 
2.5 
6.13 mths, 
DEAD 
12 67 M Tail EUS 4.9 
Solid and 
cystic body 
and tail 
mass 
PDAC UOC 
UOC and 
IPMN w/ 
HGD 
11.0 
3.17 mths, 
ALIVE 
13 59 M Head EUS 2.2 
Mass in 
head  
PDAC PDAC 
UOC  
and  
PDAC 
4.1 
5.1 mths, 
DEAD w/  
liver mets 
14 65 M Body MRI 13.0 
Solid and 
cystic mass 
in body 
PDAC UOC N/A N/A 
3.15 mths, 
ALIVE w/  
liver mets 
15 75 M Body EUS 5.4 
Solid mass 
with 1.3 cm 
cyst 
PDAC PDAC 
UOC  
and  
PDAC 
7.3 
22 mths, 
ALIVE,NED 
post chemo 
FNA, fine needle aspiration; MRI, magnetic resonance imaging; PDAC, pancreatic ductal adenocarcinoma; UOC, undifferentiated pancreatic carcinoma with osteoclastic giant cells; CT, 
computerized tomography; NET, neuroendocrine tumor; EUS, endoscopic ultrasound; NMC, neoplastic mucinous cyst; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic 
neoplasm; NED, no evidence of disease; LTF/U, lost to follow-up; Mets, metastasis; Chemo, chemotherapy; N/A, not available. 
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Table 2. Cytologic Findings in Undifferentiated Pancreatic Carcinoma with Osteoclastic Giant Cells (n=15) 
Case # 
Cytologic 
Diagnosis 
Osteoclastic 
Giant Cells 
Pleomorphi
c Giant Cells 
Spindled or 
Histiocytoid 
Cells 
PDAC 
Component 
Neutrophil
s 
Necrosi
s 
1 PDCA 1 3 1 1 2 Yes 
2 PDCA 1 3 1 1 2 Yes 
3 UOC 2 3 3 0 2 Yes 
4 UOC 3 3 3 1 2 Yes 
5 
Suspicious for 
neoplasm 
2 2 1 2 2 Yes 
6 Negative 0 0 0 1 0 No 
7 
PDAC possibly 
arising in NMC 
0 0 0 1 0 Yes 
8 PDAC  1 3 3 1 0 Yes 
9 UOC 2 2 1 0 0 No 
10 UOC 1 1 3 2 0 No 
11 PDAC 2 1 2 3 0 Yes 
12 UOC 3 3 3 0 0 Yes 
13 PDAC 3 3 2 1 0 Yes 
14 UOC 3 3 3 0 0 Yes 
15 PDAC 0 0 0 3 0 Yes 
TOTAL 
(n=15) 
 12/15 
(80%) 
12/15 
(80%) 
12/15 
(80%) 
11/15 
(73%) 
5/15 
(33%) 
Yes =12/15 
(80%) 
Frequency 
(n=45) 
 24/45  
(56%) 
30/45 
(67%) 
26/45 
(57%) 
17/45 
(38%) 
10/45  
(22%) 
 
0, absent; 1, present focally; 2, moderate amount; 3, extensive; PDCA, poorly differentiated carcinoma; UOC, undifferentiated carcinoma with osteoclastic giant cells, NMC, 
neoplastic mucinous cyst; PDAC, pancreatic ductal adenocarcinoma. 
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Table 3. Overall Patient Survival Based on Diagnosis and History of Previous FNA 
 UOC with  
Prior FNA  
(n=14) 
UOC without  
Prior FNA  
(n=27) 
PDAC with 
Prior FNA 
(n=74) 
p-value 
Median survival (mths) 8 92.4 15.6 0.0578 
1-year survival (%) 39.3 87.4 60.7  
3-year survival (%) - 57.5 31.6  
5-year survival (%) - 57.5 23  
FNA, fine needle aspiration; UOC, undifferentiated pancreatic carcinoma with osteoclastic giant cells; FNA, fine needle aspiration; 
PDAC, pancreatic ductal adenocarcinoma. 
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Legends to Figures 
 
Figure 1: Case # 4. (A) Hypercellular smear composed of 3 distinct cell types including a 
centrally located multinucleated osteoclastic giant cell surrounded by pleomorphic tumor giant 
cells and spindled and histiocytoid tumor cells (Diff Quik stain, magnification x200). (B) Tumor 
cells in a syncytial cluster including pleomorphic tumor giant cells and spindled cells with a 
multinucleated osteoclastic giant cell on the right (Papanicolaou stain, magnification x200). (C) 
Tumor giant cells are markedly pleomorphic, with nuclear irregularity and hypochromasia 
(Papanicolaou stain, magnification x400). (D) Corresponding resection in same patient showed 
a mixed conventional pancreatic ductal adenocarcinoma (upper half) and circumscribed 
undifferentiated carcinoma with osteoclastic giant cells (lower half) (Hematoxylin and eosin 
stain, magnification x40). 
 
Figure 2: Morphologic spectrum of osteoclastic giant cells: (A) Numerous multinucleated giant 
cells ranging in size from 50-500 µ are present in this example (Papanicolaou stain, 
magnification x100). (B) Osteoclastic giant cells are noted in a background of necrotic debris, 
neutrophils and rare pleomorphic tumor giant cells (Papanicolaou stain, magnification x200). 
(C) Osteoclastic giant cells have centrally clustered, bland nuclei with fine chromatin 
(Papanicolaou stain, magnification x400). (D) In this example (case # 11) Osteoclastic giant cells 
were infrequent and best seen on cell block where they had more atypical nuclei with washed 
out chromatin and large prominent nucleoli admixed with spindled tumor cells (Hematoxylin 
and eosin stain, magnification x400). 
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Figure 3: Morphologic spectrum of pleomorphic tumor giant cells. (A) Numerous singly 
dispersed epithelioid tumor cells with high nuclear to cytoplasmic ratio, irregular nuclei and 
numerous abnormal mitotic figures are seen in case # 3 (Diff Quik stain, magnification x200). (B) 
On ThinPrep these pleomorphic tumor giant cells (case # 1) have a high nuclear to cytoplasmic 
ratio with coarse chromatin and marked nuclear irregularity (Papanicolaou stain, magnification 
x400). 
 
Figure 4: Morphologic spectrum of pancreatic ductal adenocarcinoma component. (A) In this 
example (case # 11) a sheet of malignant ductal cells with nuclear hypochromasia and 
prominent nucleoli is seen with background pleomorphic tumor giant cells (Papanicolaou stain, 
magnification x200). (B) ThinPrep smear (case # 13) shows cluster of slightly pleomorphic ductal 
cells with high nuclear to cytoplasmic ratio and mild pleomorphism in a background of necrosis 
and rare single pleomorphic tumor giant cells (Papanicolaou stain, magnification x200). (C) In 
this example (case # 4) the adenocarcinoma component was more difficult to identify and was 
present as rare isolated clusters of epithelial cells with prominent cytoplasmic vacuoles 
containing targetoid mucin droplets (Papanicolaou stain, magnification x400). (D) This cell 
cluster in case # 11 is recognizable as adenocarcinoma because of the central mucin vacuole 
(Papanicolaou stain, magnification x400). 
 
Figure 5: Case # 14: (A) Core biopsy shows sheets of pleomorphic tumor giant cells, histiocytoid 
tumor cells and osteoclastic giant cells (Hematoxylin and eosin stain, magnification x400). (B) 
Osteoclastic giant cells and scattered histiocytoid tumor cells show strong positivity for CD68 
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(magnification x200). Strong diffuse positivity for p53 (C) and Ki-67 (D) is seen in pleomorphic 
and histiocytoid tumor cells but is negative in osteoclastic giant cells (magnification x200).  
 
Figure 6: Kaplan Meier survival curves show that patients with previously aspirated UOCs had a 
significantly shorter survival than their non-aspirated counterparts (8 vs 92 months; p=0.0135) 
and a comparable if not worse survival than aspirated conventional PDACs (8 vs 15 months; 
p=0.2791). This is in contrast to non-aspirated UOCs which have a longer survival (92 vs 15 
months; p=0.058) than aspirated PDACs. 
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Figure 1: Case # 4. (A) Hypercellular smear composed of 3 distinct cell types including a centrally located 
multinucleated osteoclastic giant cell surrounded by pleomorphic tumor giant cells and spindled and 
histiocytoid tumor cells (Diff Quik stain, magnification x200). (B) Tumor cells in a syncytial cluster including 
pleomorphic tumor giant cells and spindled cells with a multinucleated osteoclastic giant cell on the right 
(Papanicolaou stain, magnification x200). (C) Tumor giant cells are markedly pleomorphic, with nuclear 
irregularity and hypochromasia (Papanicolaou stain, magnification x400). (D) Corresponding resection in 
same patient showed a mixed conventional pancreatic ductal adenocarcinoma (upper half) and 
circumscribed undifferentiated carcinoma with osteoclastic giant cells (lower half) (Hematoxylin and eosin 
stain, magnification x40).  
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Figure 2: Morphologic spectrum of osteoclastic giant cells: (A) Numerous multinucleated giant cells ranging 
in size from 50-500 µ are present in this example (Papanicolaou stain, magnification x100). (B) Osteoclastic 
giant cells are noted in a background of necrotic debris, neutrophils and rare pleomorphic tumor giant cells 
(Papanicolaou stain, magnification x200). (C) Osteoclastic giant cells have centrally clustered, bland nuclei 
with fine chromatin (Papanicolaou stain, magnification x400). (D) In this example (case # 11) Osteoclastic 
giant cells were infrequent and best seen on cell block where they had more atypical nuclei with washed out 
chromatin and large prominent nucleoli admixed with spindled tumor cells (Hematoxylin and eosin stain, 
magnification x400).  
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Figure 3: Morphologic spectrum of pleomorphic tumor giant cells. (A) Numerous singly dispersed epithelioid 
tumor cells with high nuclear to cytoplasmic ratio, irregular nuclei and numerous abnormal mitotic figures 
are seen in case # 3 (Diff Quik stain, magnification x200). (B) On ThinPrep these pleomorphic tumor giant 
cells (case # 1) have a high nuclear to cytoplasmic ratio with coarse chromatin and marked nuclear 
irregularity (Papanicolaou stain, magnification x400).  
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Figure 4: Morphologic spectrum of pancreatic ductal adenocarcinoma component. (A) In this example (case 
# 11) a sheet of malignant ductal cells with nuclear hypochromasia and prominent nucleoli is seen with 
background pleomorphic tumor giant cells (Papanicolaou stain, magnification x200). (B) ThinPrep smear 
(case # 13) shows cluster of slightly pleomorphic ductal cells with high nuclear to cytoplasmic ratio and mild 
pleomorphism in a background of necrosis and rare single pleomorphic tumor giant cells (Papanicolaou stain, 
magnification x200). (C) In this example (case # 4) the adenocarcinoma component was more difficult to 
identify and was present as rare isolated clusters of epithelial cells with prominent cytoplasmic vacuoles 
containing targetoid mucin droplets (Papanicolaou stain, magnification x400). (D) This cell cluster in case # 
11 is recognizable as adenocarcinoma because of the central mucin vacuole (Papanicolaou stain, 
magnification x400).  
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Figure 5: Case # 14: (A) Core biopsy shows sheets of pleomorphic tumor giant cells, histiocytoid tumor cells 
and osteoclastic giant cells (Hematoxylin and eosin stain, magnification x400). (B) Osteoclastic giant cells 
and scattered histiocytoid tumor cells show strong positivity for CD68 (magnification x200). Strong diffuse 
positivity for p53 (C) and Ki-67 (D) is seen in pleomorphic and histiocytoid tumor cells but is negative in 
osteoclastic giant cells (magnification x200).  
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Figure 6: Kaplan Meier survival curves show that patients with previously aspirated UOCs had a significantly 
shorter survival than their non-aspirated counterparts (8 vs 92 months; p=0.0135) and a comparable if not 
worse survival than aspirated conventional PDACs (8 vs 15 months; p=0.2791). This is in contrast to non-
aspirated UOCs which have a longer survival (92 vs 15 months; p=0.058) than aspirated PDACs.  
 
59x43mm (600 x 600 DPI)  
 
 
Page 38 of 41Cancer Cytopathology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
Table 1. Clinicopathologic Characteristics of Undifferentiated Pancreatic Carcinoma with Osteoclastic giant Cells (n=15) 
FNA
# 
Age Sex Location 
Imaging 
Modality 
Size on 
Imaging 
(cm) 
Additional 
Radiologic 
Findings 
Radiologic 
Diagnosis 
Cytologic 
Diagnosis 
Histologic 
Diagnosis 
Size of 
Invasion 
(cm) 
Follow-up 
(mths) 
1 
71 F Head MRI 7.2 
Clustered 
cysts w/  
septal 
enhancement
;  
No large solid 
component 
IPMN 
Poorly 
differentiated 
carcinoma 
Mixed  
UOC  
and  
PDAC 
3.0 
10 mths, 
LTF/U after 
chemo 
2 
Poorly 
differentiated 
carcinoma 
3 54 F Body N/A N/A N/A N/A UOC UOC 2.1 
2.2 mths, 
ALIVE, NED 
4 66 F Tail MRI 6.8 
Solid and 
cystic mass 
PDAC UOC 
Mixed  
UOC and  
PDAC 
7.1 
10.2 mths, 
DEAD w/ 
liver mets 
(PDAC 
component
) 
5 51 F Head CT 3.4 
Cystic mass 
w/ 
peripheral 
nodular 
components  
Cystic  
NET 
Suspicious for 
neoplasm 
Mixed  
UOC and 
PDAC  
5.4 
4.1 mths, 
Alive, NED, 
Received 
radiation 
6 75 F Head MRI N/A 
Pancreatic 
neck 
stricture, 
severe 
pancreatic 
duct 
dilatation;  
no 
measurable 
mass 
Chronic 
pancreatitis  
vs Tumor  
Negative for 
malignant 
cells 
Mixed  
UOC and 
PDAC 
0.6 
12.9 mths, 
DEAD 
7 35 F Tail MRI 25.0 
Complex 
solid and 
cystic mass  
PDAC 
PDAC  
possibly 
arising in  
NMC 
Mixed  
UOC and 
PDAC, 
MCN w/  
HGD 
2.5 
27 mths, 
ALIVE, NED 
8 49 F Tail MRI 5.6 
Cystic and 
solid mass 
Possible 
cystic NET 
PDAC 
UOC, 
PDAC and 
MCN 
1.0 
1.2 mths, 
ALIVE w/ 
UOC liver 
mets 
9 43 M Head CT 6.0 Cystic lesion Pseudocyst UOC UOC 6.5 
21.18 mths, 
DEAD 
10 77 F Head CT 9.0 Solid mass Sarcoma UOC N/A N/A 
1.7 mths, 
DEAD 
11 65 M Head EUS 2.0 Solid mass 
PDAC vs 
lymphoma 
PDAC 
UOC and 
PDAC 
2.5 
6.13 mths, 
DEAD 
12 67 M Tail EUS 4.9 
Solid and 
cystic body 
and tail 
mass 
PDAC UOC 
UOC and 
IPMN w/ 
HGD 
11.0 
3.17 mths, 
ALIVE 
13 59 M Head EUS 2.2 
Mass in 
head  
PDAC PDAC 
UOC  
and  
PDAC 
4.1 
5.1 mths, 
DEAD w/  
liver mets 
14 65 M Body MRI 13.0 
Solid and 
cystic mass 
in body 
PDAC UOC N/A N/A 
3.15 mths, 
ALIVE w/  
liver mets 
15 75 M Body EUS 5.4 
Solid mass 
with 1.3 cm 
cyst 
PDAC PDAC 
UOC  
and  
PDAC 
7.3 
22 mths, 
ALIVE,NED 
post chemo 
FNA, fine needle aspiration; MRI, magnetic resonance imaging; PDAC, pancreatic ductal adenocarcinoma; UOC, undifferentiated pancreatic carcinoma with osteoclastic giant cells; CT, 
computerized tomography; NET, neuroendocrine tumor; EUS, endoscopic ultrasound; NMC, neoplastic mucinous cyst; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic 
neoplasm; NED, no evidence of disease; LTF/U, lost to follow-up; Mets, metastasis; Chemo, chemotherapy; N/A, not available. 
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Table 2. Cytologic Findings in Undifferentiated Pancreatic Carcinoma with Osteoclastic Giant Cells (n=15) 
Case # 
Cytologic 
Diagnosis 
Osteoclastic 
Giant Cells 
Pleomorphi
c Giant Cells 
Spindled or 
Histiocytoid 
Cells 
PDAC 
Component 
Neutrophil
s 
Necrosi
s 
1 PDCA 1 3 1 1 2 Yes 
2 PDCA 1 3 1 1 2 Yes 
3 UOC 2 3 3 0 2 Yes 
4 UOC 3 3 3 1 2 Yes 
5 
Suspicious for 
neoplasm 
2 2 1 2 2 Yes 
6 Negative 0 0 0 1 0 No 
7 
PDAC possibly 
arising in NMC 
0 0 0 1 0 Yes 
8 PDAC  1 3 3 1 0 Yes 
9 UOC 2 2 1 0 0 No 
10 UOC 1 1 3 2 0 No 
11 PDAC 2 1 2 3 0 Yes 
12 UOC 3 3 3 0 0 Yes 
13 PDAC 3 3 2 1 0 Yes 
14 UOC 3 3 3 0 0 Yes 
15 PDAC 0 0 0 3 0 Yes 
TOTAL 
(n=15) 
 12/15 
(80%) 
12/15 
(80%) 
12/15 
(80%) 
11/15 
(73%) 
5/15 
(33%) 
Yes =12/15 
(80%) 
Frequency 
(n=45) 
 24/45  
(56%) 
30/45 
(67%) 
26/45 
(57%) 
17/45 
(38%) 
10/45  
(22%) 
 
0, absent; 1, present focally; 2, moderate amount; 3, extensive; PDCA, poorly differentiated carcinoma; UOC, undifferentiated carcinoma with osteoclastic giant cells, NMC, 
neoplastic mucinous cyst; PDAC, pancreatic ductal adenocarcinoma. 
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Table 3. Overall Patient Survival Based on Diagnosis and History of Previous FNA 
 UOC with  
Prior FNA  
(n=14) 
UOC without  
Prior FNA  
(n=27) 
PDAC with 
Prior FNA 
(n=74) 
p-value 
Median survival (mths) 8 92.4 15.6 0.0578 
1-year survival (%) 39.3 87.4 60.7  
3-year survival (%) - 57.5 31.6  
5-year survival (%) - 57.5 23  
FNA, fine needle aspiration; UOC, undifferentiated pancreatic carcinoma with osteoclastic giant cells; FNA, fine needle aspiration; 
PDAC, pancreatic ductal adenocarcinoma. 
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